Thoratec upgraded to Buy from Neutral at Goldman

theflyonthewall.com

Goldman upgraded Thoratec due to an improved competitive position from recent reimbursement policy decisions, geographic expansion, new product launches and delays at competitor HeartWare. Price target raised to $46 from $40.

Rates

View Comments (0)